Data from benchmark registry demonstrate improved tavr efficiency with preserved patient safety

Paris , may 17, 2023 /prnewswire/ -- edwards lifesciences (nyse: ew) announced today that new data from the benchmark registry in europe demonstrated the safety and effectiveness of this streamlined treatment pathway for patients receiving transcatheter aortic valve replacement (tavr) with balloon-expandable valves. the data were presented in a late-breaking clinical data session at europcr 2023.
EW Ratings Summary
EW Quant Ranking